{"generic":"Methyl Aminolevulinate Hydrochloride","drugs":["Methyl Aminolevulinate Hydrochloride","Metvixia"],"mono":{"0":{"id":"929667-s-0","title":"Generic Names","mono":"Methyl Aminolevulinate Hydrochloride"},"1":{"id":"929667-s-1","title":"Dosing and Indications","sub":{"0":{"id":"929667-s-1-4","title":"Adult Dosing","mono":"<ul><li>effectiveness on more than 1 course (2 sessions scheduled 1 week apart) not established.<\/li><li><b>Actinic keratosis:<\/b> apply up to 1 gram (half tube) of cream TOPICALLY on lesion(s) during photodynamic therapy session (2 sessions 1 week apart), followed by occlusive dressing for 3 hr (at least 2.5 hr and no more than 4 hr in duration), and then red light illumination for 7 to 10 min; MAX, 1 gram (half tube) per treatment session<\/li><\/ul>"},"1":{"id":"929667-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy not established in pediatric patients under 18 years of age "},"3":{"id":"929667-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Actinic keratosis<br\/>"}}},"3":{"id":"929667-s-3","title":"Contraindications\/Warnings","sub":[{"id":"929667-s-3-9","title":"Contraindications","mono":"<ul><li>allergies to porphyrins<\/li><li>cutaneous photosensitivity, preexisting<\/li><li>hypersensitivity to methyl aminolevulinate or any component of the product, including peanut and almond oil<\/li><\/ul>"},{"id":"929667-s-3-10","title":"Precautions","mono":"<ul><li>contact sensitization has been reported; avoid contact with skin, mucous membranes, and eyes; wear nitrile gloves during application and removal of drug<\/li><li>exposure to sunlight or bright indoor light; avoid on treated lesions and surrounding skin for at least 48 hours post-photodynamic therapy (PDT); cover and protect area from light<\/li><li>prolonged exposure to drug, greater than 4 hours; should be avoided<\/li><li>redness, swelling, burning, and stinging, persisting for greater than 3 weeks posttherapy; instruct patient to contact doctor<\/li><li>treatment site photosensitivity may occur during time period between drug application and PDT; avoid exposure to sunlight, bright indoor light, and extreme cold<\/li><\/ul>"},{"id":"929667-s-3-11","title":"Pregnancy Category","mono":"Unknown<br\/>"},{"id":"929667-s-3-12","title":"Breast Feeding","mono":"Unknown<br\/>"}]},"5":{"id":"929667-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Dermatologic:<\/b>Application site edema (18%), Application site erythema (63%), Application site pain, Application site pain (Severe), Application site reaction (Severe) (22%), Blister, Burning sensation, Burning sensation (Severe), Peeling of skin (14%), Pruritus (22%), Scab of skin<br\/><b>Serious<\/b><ul><li><b>Dermatologic:<\/b>Allergic contact dermatitis, Eczema, Pustule, Urticaria<\/li><li><b>Ophthalmic:<\/b>Keratitis, Macular retinal edema, Vitreous detachment<\/li><li><b>Other:<\/b>Angioedema<\/li><\/ul>"},"6":{"id":"929667-s-6","title":"Drug Name Info","sub":{"0":{"id":"929667-s-6-17","title":"US Trade Names","mono":"Metvixia<br\/>"},"2":{"id":"929667-s-6-19","title":"Class","mono":"Photosensitizing Agent<br\/>"},"3":{"id":"929667-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"929667-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"929667-s-7","title":"Mechanism Of Action","mono":"Following topical application of methyl aminolevulinate (prodrug), it converts to photoactive porphyrins (PAPs). The accumulated PAPs in target lesions undergo light activation, resulting in a cytotoxic process in the presence of oxygen. This leads to formation of singlet oxygen and cell-damaging phototoxicity to light-exposed lesions.<br\/>"},"8":{"id":"929667-s-8","title":"Pharmacokinetics","sub":[{"id":"929667-s-8-23","title":"Absorption","mono":"bioavailability: 0.26% of applied dose after 24 hours<br\/>"}]},"9":{"id":"929667-s-9","title":"Administration","mono":"<b>General Information<\/b><br\/><ul><li>product is intended to be used by physicians in the physician's office only<\/li><li>remove scales and crusts, and roughen lesion surfaces, then apply cream topically on lesion(s) and occlusive dressing for 3 hr (at least 2.5 hr and no more than 4 hr in duration), followed subsequently by red light illumination for 7 to 10 min<\/li><li>rinse the cream off if the patient cannot have the red light illumination 3 hours after application; have patient protect exposed area from sunlight, prolonged or intense light for at least 48 hours<\/li><li>use nitrile gloves and Universal Precautions; vinyl and latex gloves do not provide adequate protection<\/li><\/ul>"},"10":{"id":"929667-s-10","title":"Monitoring","mono":"<ul><li>lesion response and cosmetic outcome at 3 months post-photodynamic therapy (PDT)<\/li><li>signs and symptoms of local skin reactions including severe burning, crusting, pustules, edema, erythema, and pain<\/li><\/ul>"},"11":{"id":"929667-s-11","title":"How Supplied","mono":"<b>Metvixia<\/b><br\/>Topical Cream: 16.8 %<br\/>"}}}